RCKT
ROCKET PHARMACEUTICALS, INC.Company Information
- Company Name
- ROCKET PHARMACEUTICALS, INC.
- CIK
- CIK0001281895
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RCKT: Nasdaq, RCKTW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RCKT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-02
- Last sale
- 2026-09-11
- Shares purchased (TTM)
- 10,000
- Shares sold (TTM)
- 286,962
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 100,133,721
- Shares outstanding
- 112,844,880
- Ownership
- 88.74%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 6.04%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 225 | 50 | 78 | 76 | 33 | 50 | 164 | 66 | 39 | 35 | 56 | 226 | ||||||
| Short Term Investments | 59 | 95 | 111 | 147 | 239 | 268 | 209 | 170 | 240 | 295 | 317 | 212 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 5 | 4 | 5 | 6 | 6 | 6 | 6 | 14 | 15 | 5 | 10 | ||||||
| Assets Current | 290 | 150 | 193 | 228 | 277 | 324 | 378 | 242 | 293 | 345 | 378 | 447 | ||||||
| Property Plant And Equipment Net | 25 | 27 | 28 | 30 | 33 | 35 | 37 | 39 | 40 | 39 | 39 | 37 | ||||||
| Goodwill | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | ||||||
| Intangible Assets Net Excluding Goodwill | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Restricted Cash Equivalents Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | ||||||
| Long Term Investments | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 34 | 0 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 4 | 4 | ||||||
| Finance Lease Right Of Use Asset | 39 | 40 | 40 | 41 | 41 | 42 | 42 | 43 | 43 | 44 | 45 | 45 | ||||||
| Assets | 423 | 285 | 330 | 368 | 421 | 471 | 528 | 394 | 446 | 499 | 566 | 599 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 28 | 22 | 27 | 28 | 41 | 32 | 38 | 37 | 35 | 30 | 46 | 31 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 31 | 24 | 30 | 31 | 43 | 35 | 41 | 40 | 38 | 33 | 49 | 33 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | ||||||
| Finance Lease Liability Noncurrent | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | ||||||
| Liabilities | 54 | 47 | 53 | 54 | 67 | 59 | 64 | 64 | 62 | 58 | 74 | 58 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Common Value | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Additional Paid In Capital | 1,733 | 1,726 | 1,717 | 1,711 | 1,702 | 1,691 | 1,680 | 1,486 | 1,475 | 1,462 | 1,451 | 1,440 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -1,366 | -1,489 | -1,441 | -1,399 | -1,348 | -1,279 | -1,218 | -1,158 | -1,091 | -1,021 | -959 | -900 | ||||||
| Stockholders Equity | 369 | 238 | 277 | 314 | 354 | 412 | 463 | 330 | 385 | 442 | 493 | 541 | ||||||
| Liabilities And Stockholders Equity | 423 | 285 | 330 | 368 | 421 | 471 | 528 | 394 | 446 | 499 | 566 | 599 | ||||||
| Series A Convertible Preferred Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series B Convertible Preferred Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 120 | 180 | 120 | ||||||
| Common Stock Shares Issued | 110 | 109 | 108 | 108 | 108 | 107 | 106 | 91 | 91 | 91 | 90 | 90 | ||||||
| Shares Outstanding | 110 | 109 | 108 | 108 | 108 | 107 | 106 | 91 | 91 | 91 | 90 | 90 | ||||||
| Treasury Stock Common Shares | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialROCKET PHARMACEUTICALS, INC. (RCKT) — SEC Financial Statements & Analysis
ROCKET PHARMACEUTICALS, INC. (RCKT) is a pharmaceutical preparations company, incorporated in DE. ROCKET PHARMACEUTICALS, INC. trades on Nasdaq as: RCKT, RCKTW. ROCKET PHARMACEUTICALS, INC. (RCKT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, ROCKET PHARMACEUTICALS, INC. carries a market cap of $385.93M, a P/E ratio of -22.37x, a P/B ratio of 1.05x, an enterprise value of $181.35M, and an EV/EBITDA multiple of -0.95x. On profitability, it posts a Return on Equity (ROE) of -4.77%, a Return on Assets (ROA) of -4.09%, and a Return on Invested Capital (ROIC) of -75.82%. Per share, it reports EPS of $-0.15, diluted EPS of $-0.15, free cash flow per share of $-1.51, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -93.30% year-over-year and EPS growth of -93.40% year-over-year. On the balance sheet, it maintains a current ratio of 9.24x, a quick ratio of 9.06x, working capital of $258.23M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, an interest coverage ratio of -101.29x, free cash flow of $-170.50M (TTM), and net debt of $-204.58M. Figures sourced from SEC EDGAR.
- Market Cap
- $385.93M
- P/E TTM
- -22.37x
- EPS TTM
- $-0.15
- P/B TTM
- 1.05x
- ROE TTM
- -4.77%
- ROA TTM
- -4.09%
- Debt To Equity
- 0.15x
- Free Cash Flow TTM
- $-170.50M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ROCKET PHARMACEUTICALS, INC. in?
ROCKET PHARMACEUTICALS, INC. (RCKT) operates in the Pharmaceutical Preparations industry.
What exchange does RCKT trade on?
ROCKET PHARMACEUTICALS, INC. (RCKT) trades on the Nasdaq.
Where is ROCKET PHARMACEUTICALS, INC. incorporated?
ROCKET PHARMACEUTICALS, INC. is incorporated in DE.
When was ROCKET PHARMACEUTICALS, INC. (RCKT)'s most recent SEC filing?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is RCKT's market cap?
ROCKET PHARMACEUTICALS, INC. (RCKT) has a market capitalization of $385.93M as of 2026-06-30.
What is RCKT's EPS (earnings per share)?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s trailing twelve month EPS is $-0.15 as of 2026-06-30.
What is RCKT's ROE (return on equity)?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s trailing twelve month Return on Equity (ROE) is -4.77% as of 2026-06-30.
What is RCKT's ROA (return on assets)?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s trailing twelve month Return on Assets (ROA) is -4.09% as of 2026-06-30.
What is RCKT's ROIC (return on invested capital)?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s trailing twelve month Return on Invested Capital (ROIC) is -75.82% as of 2026-06-30.
What is RCKT's EV/EBITDA?
ROCKET PHARMACEUTICALS, INC. (RCKT)'s trailing twelve month EV/EBITDA is -0.95x as of 2026-06-30.